Special Issue "Advances in the Radiography of Prostate Cancer"

A special issue of Tomography (ISSN 2379-139X).

Deadline for manuscript submissions: 30 December 2022 | Viewed by 438

Special Issue Editor

Dr. Tore Bach-Gansmo
E-Mail Website
Guest Editor
Department of Radiology and Nuclear Medicine, University Hospital of North Norway, 9019 Tromsø, Norway
Interests: PET-CT; prostate cancer

Special Issue Information

Dear Colleagues, 

Today, PET/CT has a profound influence on diagnostic work in prostate cancer, where MR alone was the leading technology for a decade. Today, multimodality imaging is striving to find the correct balance between cost and benefit. The possibility of PET/MR has not, or not yet, resulted in a major change to this modality. This may be due both to the relative paucity of PET/MR and inherent difficulties in the technology.

On top of technological advances, we can observe a multitude of other possibilities that are invading our field. A number of PET tracers are used or under development. An impressive number of PSMA analogues, based on generator-based 67Ga-gallium or cyclotron-based 18F-flour, are under development. The last word on their respective sensitivity and specificity has not yet been uttered.

Not least, the new treatment possibility with protein receptor radionuclides has produced amazing results in clinical trials, and they are on the verge of marketing authorization, possibly changing the prognosis of a vast number of patients.

There is a plentitude of potential new knowledge, leaving us with a number of stones unturned, hence this Special Issue.

Papers of high academic standard addressing these and related topics are invited to this Special Issue. We are looking for results from clinical and preclinical studies and papers identifying unmet needs or challenges related to the field of imaging and nuclear-medicine-based therapeutics.

Dr. Tore Bach-Gansmo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Tomography is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • MR
  • PET/MR
  • PET/CT
  • F/Ga-PSMA
  • PSMA therapeutic use
  • FDG
  • FACBC

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Communication
Diagnostic Performance of Preoperative Choline-PET/CT in Patients Undergoing Salvage Lymph Node Dissection for Recurrent Prostate Cancer: A Multicenter Experience
Tomography 2022, 8(2), 1090-1096; https://doi.org/10.3390/tomography8020089 - 11 Apr 2022
Viewed by 335
Abstract
We aimed to retrospectively analyze consecutive prostate cancer patients diagnosed with biochemical or clinical recurrence after local treatment with curative intent, with no evidence of distant metastases, who underwent positron emission tomography/computed tomography (PET/CT) with choline followed by salvage lymph node dissection (SLND) [...] Read more.
We aimed to retrospectively analyze consecutive prostate cancer patients diagnosed with biochemical or clinical recurrence after local treatment with curative intent, with no evidence of distant metastases, who underwent positron emission tomography/computed tomography (PET/CT) with choline followed by salvage lymph node dissection (SLND) in three academic centers between 2013 and 2020. A total of 27 men were included in the analyses. Sensitivity, specificity, positive and negative predictive values, and accuracy of choline-PET/CT in predicting pathology-proven lymph node involvement were 75%, 43%, 79%, 38% and 67% on per-patient and 70%, 86%, 80%, 78%, and 79% on per-site analyses, respectively, with the differences in specificity and NPV between per-patient and per-site analyses being statistically significant (p = 0.03 and 0.04, respectively). The study provides further insight into the role of preoperative choline-PET/CT in patients undergoing SLND for recurrent PC. Full article
(This article belongs to the Special Issue Advances in the Radiography of Prostate Cancer)
Back to TopTop